$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

A drug delivery system(DDS) for practically insoluble meloxicam was developed and evaluated by dissolution study. A novel DDS is two layered system, where the first layer is consisted of gas-forming agent for an immediate release and the second layer is composed of metolose SR(HPMC) for sustained release. This bilayered tablets were manufactured by using manual single punch machine. The results of dissolution study showed an initial burst release followed by sustained release for the experimental period time. From a pharmaceutical point of view, the designed DDS for meloxicam would be informative system in terms of poorly soluble analgesic medicines.

참고문헌 (21)

  1. S. Gupta and L.-J. Crofford, An Update on specific COX-2 inhibitors: The COXIBs, Bulletin on the Rheumatic Disease., 50(1), 5245-5248 (2001) 
  2. Rxlist, Mobic, Meloxicam, Pharmacology & Clinical review, US medicinal information 
  3. M. Pairet, J. van Ryn, H. Schierok, A Mauz, G. Trummlitz and G. Engelhardt, Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. lnflamm Res., 47(6), 270-276 (1998) 
  4. E-M. Andreas, K.-D. Christine, H. Nina, H. Stefan, S. Jens and K.-H. Juergen, Water-so;uble meloxicam granulates, PCT W02004037264 
  5. K. Laura, P. John, C.-R. Eugene and R. Tuula, Nanoparticulate meloxicam formulations, US patent US2004229038 
  6. S. Baroota, S.-P. Agarwal, Meloxicam complexation with ${\beta}$-cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity, 58, 73-74 (2003) 
  7. N.-B. Naidu, K.P.R. Chowdary, K.Y.R. Murthy, Y. Satyanarayana, A.-R. Hayman and G. Heeket, Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems, Journal of Pharmaceutical and Biomedical Analysis, 35, 75-86 (2004) 
  8. M.-M. Ghorab, H.-M. Abdel-Salam, M.-A EI-Sayad and M.-M. Mekhel, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation, AAPS Pharm. Sci. Tech., 27(5) , e59 (2004) 
  9. J. Dequeker, and F. degner, Inflammation Research Editorial, lnflamm. Res., 50, Supplement 1 S3-S4 (2001) 
  10. E.-M. Lemmel, W. Bolten, R. Burgos-Vargns, P. Platt, M. Nissila, D. Sahlberg, et al., Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatopl., 24, 282-290 (1997) 
  11. B. Lund, M. Dialel, R. Bluhmki and A double-blind, randomized placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J. Rheumatol, 27, 32-37 (1998) 
  12. D. Vocum, D. Hall, and P. Ruszko, Meloxicam osteoarthritis team. Efficacy and safety of meloxicam in the treatment of osteoarthritis. Arthr Rheum., 42(Suppl), S147 (1999) 
  13. M. Dougados, A. Gueguen, J.-P. Nakache, I. Veys, E.-M. Zeildler, et a!., Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology, 38, 235-244 (1999) 
  14. D. Duchene, D. Wouessidiewe, Pharmaceutical uses of cyclodextrins and derivatives, Drug Dev. lnd. Pharm., 16, 2487-2499 (1990) 
  15. O. Berkers, E.Y. Uijioridal, J.-H. Haijnen, A. Bult and W.-J. Underberg, Cyclodextrins in the pharmaceutical field. Drug Dev. lnd. Pharm. 17, 1503-1549 (1991) 
  16. Ludipress, Technical information, BASF Chem. Co., Supersedes issue of October 2001, September, 2003 
  17. Metolose SR (Hypromellose), Technical note, ShinEtsu Chem. Co., issued on October, 2002 
  18. B. Pose-Vilamovo, C. Rodriguez-Tenreiro, J.-F. Rosa dos Santos, J. Vazquez-Doval, A. Concheiro, C. Alvarez-Lorenzo and J.-J. Torres-Labandeira, Modulating drug release with cyclodextrins in hydroxypropyl methylcellulose gels and tablets. J. Control Release. 10;94(2-3), 351-363 (2004) 
  19. R.-O. Williams 3rd, M.-A .Sykora and V. Mahaguna, Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. AAPS Pharm. Sci. Tech. Jun, 9;2(2):E8 (2001) 
  20. D.-X. Zhejiang, B. Xue and Y.-X. Ban. Investigation on release model of insoluble drug in hydroxypropyl methycellulose matrix tablets, 33(3), 225-228 (2004) 
  21. R. Banerjee, H. Chakraborty and M. Sarkar, Host-Guest complexation of oxicam NSAIDs with ${\beta}$-cyclodextrin, Biopolymers, 75(4), 355-365 (2004) 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일